Cellvera is a biopharmaceutical company focused on discovering, developing and commercializing oral therapies and monitoring tools to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleotide chemistry, biology, biochemistry and virology, Cellvera has built a nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Cellvera is focused on the clinical and commercial development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV). Cellvera also holds the exclusive commercial rights for Avigan in Russia and China.

​

Driven to Discover
Cellvera’s team includes PhDs in computational biology, biochemistry, and chemistry, as well as senior software engineers. We’re driven by the confidence that medicine’s greatest discoveries lie ahead, and are now within reach.